Moderna, Inc. vs Johnson & Johnson
MRNA vs JNJ — side-by-side comparison from reported financials. MRNA leads 3, JNJ leads 7 of 10 comparable metrics.
Moderna, Inc.
MRNA · Healthcare
$225.15+14.29%Strong
Johnson & Johnson
JNJ · Healthcare
$261.79+2.07%Mixed
| Metric | MRNA | JNJ |
|---|---|---|
| Price | $225.15 | $261.79 |
| Market cap | $89.9B | $631B |
| Revenue (TTM) | $2.23B | $97.9B |
| Revenue growth | -53.4% | +5.6% |
| Net margin | -141.4% | 21.5% |
| Free cash flow | -$1.24B | $22.2B |
| Net cash (debt) | $5.21B | ($27.8B) |
| 1-year price return | +717.8% | +37.0% |
| P/E | 3.9 | 29.9 |
| P/E vs own history (cheap-side %) | 10% | 16% |
| Dividend yield | — | 2.00% |
| Return on equity | -39% | 26% |
| Altman Z-score | 13.40 | — |
| CV checks passed | 6 of 10 | 10 of 10 |
| Employees | 4,700 | 140,800 |
Full résumé-style profiles: MRNA CV · JNJ CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.